RBC Capital Reiterates Outperform on Edwards Lifesciences, Maintains $96 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Shagun Singh has reiterated an 'Outperform' rating on Edwards Lifesciences (NYSE:EW) and maintained a price target of $96.
July 27, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences (NYSE:EW) has been reiterated as 'Outperform' by RBC Capital, with a maintained price target of $96.
The reiteration of an 'Outperform' rating by a reputable analyst like Shagun Singh from RBC Capital is a positive signal for Edwards Lifesciences. The maintained price target of $96 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100